Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

MT Newswires Live09-23

Travere Therapeutics (TVTX) said Wednesday that it received a notice of allowance from the US Patent and Trademark Office for certain methods of using FILSPARI in focal segmental glomerulosclerosis, a rare kidney disease.

The company said it expects to receive the patent, which is expected to provide US patent coverage for certain methods of using FILSPARI in the disease into October 2037, after paying the issue fee and completing standard USPTO post-allowance processing.

Travere said it expects to submit the patent for listing in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations after receiving the grant.

Shares of the company were down 1.3% in Wednesday's premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2669848334?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-23 19:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669848334","market":"us","top_or_hot":-1,"title":"Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI","media":"MT Newswires Live","content":"<html><body><p> Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TVTX) said Wednesday that it received a notice of allowance from the US Patent and Trademark Office for certain methods of using FILSPARI in focal segmental glomerulosclerosis, a rare kidney disease.</p><p>The company said it expects to receive the patent, which is expected to provide US patent coverage for certain methods of using FILSPARI in the disease into October 2037, after paying the issue fee and completing standard USPTO post-allowance processing.</p><p>Travere said it expects to submit the patent for listing in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations after receiving the grant.</p><p>Shares of the company were down 1.3% in Wednesday's premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-23 19:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TVTX) said Wednesday that it received a notice of allowance from the US Patent and Trademark Office for certain methods of using FILSPARI in focal segmental glomerulosclerosis, a rare kidney disease.</p><p>The company said it expects to receive the patent, which is expected to provide US patent coverage for certain methods of using FILSPARI in the disease into October 2037, after paying the issue fee and completing standard USPTO post-allowance processing.</p><p>Travere said it expects to submit the patent for listing in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations after receiving the grant.</p><p>Shares of the company were down 1.3% in Wednesday's premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2669848334","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669848334","pubTimestamp":1790164165,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Travere Therapeutics  said Wednesday that it received a notice of allowance from the US Patent and Trademark Office for certain methods of using FILSPARI in focal segmental glomerulosclerosis, a rare kidney disease.The company said it expects to receive the patent, which is expected to provide US patent coverage for certain methods of using FILSPARI in the disease into October 2037, after paying the issue fee and completing standard USPTO post-allowance processing.Travere said it expects to submit the patent for listing in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations after receiving the grant.Shares of the company were down 1.3% in Wednesday's premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","TVTX":"Travere Therapeutics, Inc.","USRD":"THEMES US R&D CHAMPIONS ETF","FFTY":"Innovator IBD 50 ETF","LFSC":"F/m Emerald Life Sciences Innovation ETF","BK4539":"次新股","LENZ":"Therapeutics"},"translate_title":"Travere Therapeutics 获得肾病药物 FILSPARI 的美国专利授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1,"LENZ":1.5,"LFSC":0.6,"USRD":0.6,"FFTY":1.5},"content_text":"Travere Therapeutics (TVTX) said Wednesday that it received a notice of allowance from the US Patent and Trademark Office for certain methods of using FILSPARI in focal segmental glomerulosclerosis, a rare kidney disease.The company said it expects to receive the patent, which is expected to provide US patent coverage for certain methods of using FILSPARI in the disease into October 2037, after paying the issue fee and completing standard USPTO post-allowance processing.Travere said it expects to submit the patent for listing in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations after receiving the grant.Shares of the company were down 1.3% in Wednesday's premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669848334","isCrawlerRequest":true}